BSECompany Update2d ago · 16 Nov 2026, 01:04 pm
Pls. find enclosed herewith Investor Presentation.
Dishman Carbogen Amcis Ltd · 540701
✦ AI SummaryResults
Dishman Carbogen Amcis Ltd has released its un-audited financial results for the second quarter and half year ended September 30, 2026, showing a decline in revenue and net profit compared to the same period last year.
Analysis Scores
Earnings Impact4/10
Growth Catalyst5/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk2/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Dishman Carbogen Amcis Ltd - 540701 - Announcement under Regulation 30 (LODR)-Investor Presentation
Attachments (1)
📄pdf
Download →
e7dadc06-3a5e-4b20-923e-d4fc4d2b560d.pdf
View document text
16th November, 2026
To, To,
Department of Corporate Services The Manager,
BSE Ltd. Listing Department,
Phiroze Jeejeebhoy Towers, National Stock Exchange of India Ltd.
Dalal Street, “Exchange Plaza”, C-1, Block G,
Mumbai – 400 001. Bandra-Kurla Complex,
Bandra (E), Mumbai – 400 051.
Ref.: Scrip Code No. : 540701 (Equity) Ref. : (i) Symbol – DCAL
: 975834, 976560, 977467, 977859, 978062, (ii) Series – EQ
978230 and 978323 (Debt)
SUB: INVESTORS PRESENTATION ON UN-AUDITED FINANCIAL RESULT FOR THE
SECOND QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2026 –
REGULATIONS: 30 and 51
Dear Sir,
Pursuant to Regulations 30 and 51 of the SEBI (Listing Obligations and Disclosures
Requirements) Regulations, 2015, pls. find enclosed herewith Presentation on Un-
Audited financial result for the second quarter and half year ended 30th September,
2026 to be made to Analyst and Investors.
The aforesaid presentation is also being hosted on the website of the Company,
www.imdcal.com in accordance with the Regulations 46 and 62 of the SEBI (Listing
Obligations and Disclosures Requirements) Regulations, 2015.
Kindly take the same on your record.
Yours faithfully,
For, Dishman Carbogen Amcis Limited
Shrima Dave
Company Secretary
Encl.: As above
Investor Presentation
Q2FY27 & H1FY27
Quater ended September 30, 2026
This presentation and the following discussion may contain “forward looking statements”
by Dishman Carbogen Amcis Limited (‘Dishman’ or the ‘Company’) that are not historical in
nature. These forward-looking statements, which may include statements relating to future
results of operations, financial condition, business prospects, plans and objectives, are
based on the current beliefs, assumptions, expectations, estimates, and projections of the
management of Dishman about the business, industry and markets in which Dishman
operates.
SAFE HARBOR
These statements are not guarantees of future performance, and are subject to known and
unknown risks, uncertainties, and other factors, some of which are beyond Dishman’s
STATEMENT
control and difficult to predict, that could cause actual results, performance or
achievements to differ materially from those in the forward-looking statements. Such
statements are not, and should not be construed, as a representation as to future
performance or achievements of Dishman.
In particular, such statements should not be regarded as a projection of future performance
of Dishman. It should be noted that the actual performance or achievements of Dishman
may vary significantly from such statements.
23 32 4
Solving Complex Problems for
250+
Multi-Purpose MANUFACTURING RESEARCH & DEVELOPMENT Successful IN-ORGANIC
Clients
FACILITIES Globally and HIPO LABS GROWTH TRANSACTIONS
DISHMAN IN Global Health Authorities CHF 98 M 2,100+ Team Strength
decades
Committed Members Embracing
Approved & Recognized by our Culture of Innovation &
A NUTSHELL of Long-Standing Track Record in NEW PRODUCT Sustainability
DEVELOPMENT PIPELINE
CDMO USFDA, MEB, SWISS MEDIC, Dedicated Team/Scientist Working
SPECIALTIES, QUATS & ANSM, WHO, MFDS, PMDA, in R&D - 950+
GENERICS NMPA, EDQM 50% of Technical Staff holding Ph.D
Commencement
13 30 Successful First
Operations in
of tech transfer of
FDA Pre-Approval
second molecule
India, Switzerland, UK, Inspection at Its
France, China and the Late Phase Total from Switzerland
Commercialized Vionnaz Site
Netherlands
III molecules
Molecules to India
Revenue from Operations (₹ mn) EBITDA (₹ mn) and EBITDA %
EBITDA EBITDA %
19.3%
17.3%
15.5%
14.3% 13.8%
11.0%
HISTORICAL 0 7 9 8 5 9
2 0 2 5 1 1 3 4 2 5 0 6
1 4 1 1 1 3 4 1 2 6 9 5
, , , , , , 7 3 3 8 6 6
9 1 4 6 7 9
1 2 2 2 2 2 ,2 ,3 ,3 ,2 ,4 ,5
FINANCIAL FY21 FY22 FY23 FY24 FY25 FY26 FY21 FY22 FY23 FY24 FY25 FY26
Strong basket of 14 molecules in
Late Phase III development.
PERFORMANCE CDMO (₹ mn) Marketable Molecules (₹ mn)
4 3 3 0 0 3
2 9 5 8 3 1 6 4 6 9 5 6
3 4 4 6 9 4 9 1 7 7 8 0
, 4 , 6 , 9 , 1 , 2 , 4 7 9 6 4 1 9
1 1 1 2 2 2 ,4 ,4 ,4 ,4 ,4 ,4
FY21 FY22 FY23 FY24 FY25 FY26 FY21 FY22 FY23 FY24 FY25 FY26
AGENDA
01 02 03
Quarter & Half Company Industry
Year Highlights Overview Overview
02 03
Quarter &
Company Industry
Half Year Overview Overview
Highlights
NET REVENUE (₹ mn) EBITDA (₹ mn) & EBITDA MARGIN (%)
22.8%
26.0%
21.0%
16.0%
9.1%
11.0%
6,527 5,074 1,489 460 6.0%
1.0%
Q2FY26 Q2FY27 Q2FY26 Q2FY27
Q2FY27 RESULT
HIGHLIGHTS SEGMENT WISE REVENUE BREAKUP (₹ mn)
1,433
1,186
5,094 3,887
Q2FY26 Q2FY27
CDMO Marketable Molecules
NET REVENUE (₹ mn) EBITDA (₹ mn) & EBITDA MARGIN (%)
21.3% 26.0%
21.0%
16.0%
8.9%
11.0%
13,607 11,850 2,896 1,060 6.0%
1.0%
H1FY26 H1FY27 H1FY26 H1FY27
H1FY27 RESULT
HIGHLIGHTS SEGMENT WISE REVENUE BREAKUP (₹ mn)
2,401
2,560
11,206 9,290
H1FY26 H1FY27
CDMO Marketable Molecules
Particulars (₹ mn) Q2FY27 Q2FY26 YoY % H1FY27 H1FY26 YoY %
Income from Operations (Net) 5,073.7 6,526.5 -22.3% 11,850.1 13,607.0 -12.9%
COGS 347.8 343.1 1.4% 1,490.1 1,324.0 12.5%
Employee Expenses 3,216.2 3,329.4 -3.4% 7,107.2 6,848.4 3.8%
Other Expenses 1,050.1 1,365.1 -23.1% 2,192.4 2,538.9 -13.6%
EBITDA 459.6 1,488.9 -69.1% 1,060.4 2,895.7 -63.4%
EBIDTA Margin % 9.1% 22.8% 8.9% 21.3%
CONSOLIDATED
Other Income 35.6 81.1 -56.1% 217.2 328.6 -33.9%
Depreciation & Amortization 904.2 841.3 7.5% 1,811.0 1,654.8 9.4%
P&L STATEMENT
Finance Cost (Incl. Forex Impact) 401.0 423.3 -5.3% 771.9 850.9 -9.3%
Exceptional Items (16.9) (26.5)
Profit Before Tax (810.0) 305.4 -365.2% (1,322.2) 692.1 -291.0%
Tax Expense (142.7) (347.3) (76.1) (194.7)
Profit After Tax (667.3) 652.7 -202.2% (1,246.1) 886.8 -240.5%
PAT Margin % -13.2% 10.0% -10.5% 6.5%
Particulars (₹ mn) Sep-26 Mar-26 Particulars (₹ mn) Sep-26 Mar-26
Property, plant and equipment 28,098.9 29,419.3
Equity Share Capital 313.6 313.6
Capital Work in Progress 2,919.3 2,750.0
Other Equity 66,397.1 66,455.4
Right to use Lease Assets 1,870.7 2,262.9
Total - Shareholder Funds 66,710.7 66,769.0
Investment property 43.4 45.6
Goodwill 46,807.9 47,984.1 Long Term Borrowings 15,317.5 15,348.6
Other Intangible Assets 876.5 1,043.7
Lease Liabilities 1,798.0 2,232.9
Intangible Assets under development 3,237.0 2,953.1
Other Financial Liabilities 229.8 288.1
Investments 752.8 752.8
Provisions 2,287.3 4,279.3
Long Term Loans and Advances 19.2 19.0
Other Financial Assets 183.1 194.0 Deferred Tax Liabilities (Net) 248.2 119.1
Deferred tax assets (net) 777.2 833.6
Other Non-Current liabilities 4,158.9 7,025.6
CONSOLIDATED
Current Tax Assets 966.6 1,300.4
Total - Non-Current Liabilities 24,039.7 29,293.6
Other Non-Current Assets 1,270.3 1,253.6
Short Term Borrowings 16,319.4 12,405.4
Balance Sheet Total - Non-Current Assets 87,822.9 90,812.1
Inventories 11,127.6 10,191.2 Lease Liabilities 736.6 773.7
Investments 166.2 161.7
Trade Payables 2,754.3 2,111.8
Trade Receivables 4,703.9 6,729.1
Other Financial Liabilities 2,223.3 3,490.2
Cash and cash equivalents 10,090.9 7,877.6
Other Current Liabilities 4,565.0 3,358.2
Bank balances 1,961.8 2,034.5
Short Term Loans and Advances 33.4 32.5 Short Term Provisions 19.5 143.3
Other Financial Assets 493.3 234.2 Current Tax Liabilities (Net) 592.5 887.9
Other Current Assets 1,561.0 1,160.2
Total - Current Liabilities 27,210.6 23,170.5
Total - Current Assets 30,138.1 28,421.0
Total - Equities & Liabilities 1,17,961.0 1,19,233.1
Total - Assets 1,17,961.0 1,19,233.1
As per Reported figures
Revenue (₹ mn) Q2FY27 Q2FY26 H1FY27 H1FY26
CDMO 3,887.5 5,094.0 9,290.4 11,206.4
Marketable Molecules 1,186.2 1,432.5 2,559.7 2,400.6
Total Revenue 5,073.7 6,526.5 11,850.1 13,607.0
REVENUE Total Operating Revenue – Q2FY27 Total Operating Revenue – H1FY27
BREAKUP
23% 22%
ANALYSIS & CDMO
H1FY27
Q2FY27
MARGIN
Marketable Molecules
BREAKUP 77% 78%
ANALYSIS
EBITDA Margin % Q2FY27 Q2FY26 H1FY27 H1FY26
CDMO 12.3% 25.3% 8.7% 21.3%
Marketable Molecules -1.6% 14.0% 9.7% 21.4%
➢ Net Revenue at ₹ 11,805 mn in H1FY27 down by 12.9% YoY, primarily due to lower revenue
from CDMO segment.
➢ CDMO revenue declined by 17.1% YoY in H1FY27, mainly due to lowe
[Showing first 8,000 characters — download PDF for full document]